A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg

NCT00464308 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

1392

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastro-oesophageal Reflux

Interventions

DRUG: Esomeprazole
DRUG: Rabeprazole
DRUG: Esomeprazole

Sponsor

Janssen-Cilag Pty Ltd